Cybin and Greenbrook announce partnership to roll out clinic expansion and development of psychedelic therapies.
The DEA approved shipment is a milestone toward legal access to psilocybin mushrooms for U.S. clinical research and health treatments.
Some leading developers of psychedelic medicines are focusing on both plant-derived and synthetic molecules to create unique therapies.
Lindsay Hoover of the JLS Fund examines the market strategies of five publicly traded companies favored by investors to bring psychedelic-assisted therapy to the mainstream.
Cryptocurrencies such as Bitcoin have funded psychedelic research and may pave the way for financial systems that replicate more decentralized psychedelic business structures.
Canada-based Red Light Holland is selling psilocybin truffles in the Netherlands where they are legal and eyeing other markets for non-medical use of psychedelics.
Cybin is using the Flow neuroimaging technology developed by Kernel to create targeted and customized doses of psychedelic compounds for mental health treatment.
The mainstreaming of psychedelics has led to the formation of a new wave of professional organizations to establish best practices for the entheogenic frontier.
Therapies using small amounts of psychedelic compounds may be the future of pain management.
In this week’s Trip Report: Harvard Law students ask if psychedelics can help save America; a new book covers the role of psychedelics in ancient religions; the Canadian parliament is on the clock to decriminalize psychedelics; and more.